Back

The influence of gender on 1-year outcomes of patients undergoing primary AF ablation

26 August 2017 (12:35 - 13:25)
Organised by:
Congress Presentation Part of: Atrial fibrillation ablation - Outcomes and predictors Atrial fibrillation (AF) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Doctor Melissa Middeldorp

University of Adelaide, Adelaide (Australia)

5 More presentations in this session

Presentation thumbnail
Atrial fibrillation relapse after a single catheter ablation procedure - an up to 10 years follow-up analysis
Doctor J. Mesquita (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Longer duration of persistent atrial fibrillation episodes prior to catheter ablation is associated with lower freedom of atrial arrhythmias after catheter ablation
Doctor N. Naksuk (Omaha, US)
Abstract Slides
Presentation thumbnail
Short- and long-term efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials
Doctor A. Parwani (Berlin, DE)
Abstract Slides
Presentation thumbnail
Long term outcome following mitral valve repair or replacement: the impact of concomitant atrial fibrillation treatment and sinus rhythm restoration.
Professor C. Muneretto (Brescia, IT)
Abstract Slides
Presentation thumbnail
Identification of predictors for atrial fibrillation-free survival after catheter ablation of persistent atrial fibrillation-results from a large prospective cohort
Doctor K. Koch-Buettner (Munich, DE)
Abstract Slides

Access the full session

Session thumbnail
Atrial fibrillation ablation - Outcomes and predictors

The Event

Event poster

ESC Congress 2017

26 August 2017 12:35 CET
You may be interested in
thumbnail
Congress Presentation
1 September 2019
thumbnail
Congress Session
Comorbidity management in patients presenting with atrial fibrillation – the EHRA-PATHS Project
7 April 2024
thumbnail
Congress Presentation
EP lab: in 2025, is gender still a factor?
1 April 2025
thumbnail
Congress Presentation
Gender-specific aspects of long-term CryoPVI efficacy
7 April 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources